Latest Period
Q1 2026
Security Snapshot
Maze Therapeutics, Inc. - Common Stock (MAZE) Institutional Ownership
CUSIP: 578784100
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
164
Shares (Excl. Options)
51,677,471
Price
$29.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- MAZE on Nasdaq
- Shares outstanding
- 49,290,966
- Price per share
- $26.47
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 51,677,471
- Total reported value
- $1,543,189,088
- % of total 13F portfolios
- 0%
- Share change
- +3,214,670
- Value change
- +$68,963,225
- Number of holders
- 164
- Price from insider filings
- $26.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- MAZE - Maze Therapeutics, Inc. - Common Stock is tracked under CUSIP 578784100.
- 164 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 144 to 164 between Q4 2025 and Q1 2026.
- Reported value moved from $2,003,833,642 to $1,543,189,088.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 164 institutions filings for Q1 2026.
Security key
578784100
Latest holder period
Q1 2026
13F holders
164
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
MAZE full holder history
Maze Therapeutics, Inc. SEC filings
Maze Therapeutics, Inc. company facts
Maze Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 578784100:
Significant Owners of Maze Therapeutics, Inc. - Common Stock (MAZE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 9.3% | -33% | $179,808,372 | -$64,304,000 | 4,473,958 | -26% | Third Rock Ventures IV, L.P. | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 9% | +16% | $174,515,671 | +$39,762,017 | 4,342,266 | +30% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| ARCH Venture Fund X, L.P. | 9.4% | $36,215,266 | 4,120,053 | ARCH Venture Fund X, L.P. | 31 Mar 2025 | |||
| Deep Track Capital, LP | 9% | +30% | $59,431,096 | +$13,927,661 | 3,948,910 | +31% | Deep Track Capital, LP | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 6.1% | $155,788,502 | 3,051,087 | Paradigm BioCapital Advisors LP | 25 Mar 2026 | |||
| JANUS HENDERSON GROUP PLC | 5.8% | -21% | $78,390,380 | -$9,531,082 | 2,858,876 | -11% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Matrix Capital Management Company, LP | 3.5% | -37% | $42,880,026 | -$21,586,725 | 1,653,684 | -33% | Matrix Capital Management Company, LP | 30 Sep 2025 |
| GV 2019, L.P. | 2.9% | -52% | $57,528,994 | -$42,419,680 | 1,388,583 | -42% | Alphabet Holdings LLC | 31 Dec 2025 |
| Foresite Capital Fund IV, L.P. | 1.4% | -70% | $15,790,022 | -$47,922,789 | 608,948 | -75% | James Tananbaum | 30 Sep 2025 |
As of 31 Mar 2026, 164 institutional investors reported holding 51,677,471 shares of Maze Therapeutics, Inc. - Common Stock (MAZE). This represents 105% of the company’s total 49,290,966 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Maze Therapeutics, Inc. - Common Stock (MAZE) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 9.3% | 4,567,274 | 0% | 3.5% | $136,333,129 |
| TRV GP IV, LLC | 9.1% | 4,473,958 | 0% | 50% | $133,547,646 |
| ARCH Venture Management, LLC | 8.4% | 4,120,053 | 0% | 18% | $122,983,582 |
| Deep Track Capital, LP | 7.1% | 3,477,562 | -18% | 2.1% | $103,805,226 |
| JANUS HENDERSON GROUP PLC | 5.8% | 2,858,876 | -9% | 0.04% | $85,280,271 |
| Paradigm Biocapital Advisors LP | 5.6% | 2,744,399 | 1.7% | $81,920,310 | |
| BlackRock, Inc. | 5.2% | 2,570,425 | +12% | 0% | $76,727,187 |
| a16z Capital Management, L.L.C. | 3.5% | 1,702,225 | 0% | 3.9% | $50,811,416 |
| Venrock Adviser, LLC | 3.3% | 1,602,034 | +3.5% | 1.8% | $47,820,715 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 1,435,656 | 0% | 0% | $42,854,332 |
| Alphabet Inc. | 2.8% | 1,388,583 | 0% | 1% | $41,449,203 |
| Logos Global Management LP | 2.5% | 1,235,000 | +30% | 1.9% | $36,864,750 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.4% | 1,178,000 | 0.05% | $35,163,300 | |
| General Catalyst Group Management, LLC | 2.1% | 1,035,910 | 0% | 17% | $30,921,914 |
| TRV GP V, LLC | 1.9% | 950,800 | 0% | 7.1% | $28,381,380 |
| FMR LLC | 1.8% | 864,214 | +19% | 0% | $25,796,788 |
| CITADEL ADVISORS LLC | 1.6% | 775,714 | +73% | 0.02% | $23,155,063 |
| ArrowMark Colorado Holdings LLC | 1.6% | 767,383 | 0% | 0.61% | $22,906,383 |
| Casdin Capital, LLC | 1.5% | 758,857 | 0% | 1.7% | $22,651,881 |
| Cormorant Asset Management, LP | 1.5% | 750,000 | 1.1% | $22,387,500 | |
| Woodline Partners LP | 1.3% | 650,229 | -37% | 0.07% | $19,409,336 |
| STATE STREET CORP | 1.3% | 636,722 | +19% | 0% | $19,006,152 |
| Driehaus Capital Management LLC | 1.3% | 636,162 | +68% | 0.14% | $18,989,436 |
| Caligan Partners LP | 1.2% | 614,962 | +12% | 1.3% | $18,356,616 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 599,967 | +14% | 0% | $17,912,855 |
Institutional Holders of Maze Therapeutics, Inc. - Common Stock (MAZE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 51,677,471 | $1,543,189,088 | +$68,963,225 | $29.85 | 164 |
| 2025 Q4 | 48,370,369 | $2,003,833,642 | +$199,439,391 | $41.43 | 144 |
| 2025 Q3 | 42,970,633 | $1,114,223,528 | +$108,250,260 | $25.93 | 93 |
| 2025 Q2 | 38,836,437 | $476,719,891 | -$14,337,293 | $12.27 | 74 |
| 2025 Q1 | 40,038,674 | $441,393,439 | +$441,263,796 | $11.01 | 68 |